Catalyst
Slingshot members are tracking this event:
Genentech (RHHBY) Presents Phase 3 HAVEN 1 Results Evaluating Emicizumab in Patients at Least 12 Years Old with Hemophilia A and Inhibitors to Factor VIII
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Haven 1, Emicizumab, 12 Years Old, Hemophilia A, Factor Viii
